However, the results of our study revealed that the anti-cancer efficacy of p28 is directly dependent on the presence of p53 suggesting its inapplicability as a therapeutic agent in cancers with null-p53 status such as HPV-related cervical cancers. This evidence concerns the gene TP53 and cervical carcinoma.